Treventis scientists and advisors attend and present at ALS/MND 2020

Treventis scientists Drs. Christopher Barden and Ross Mancini and SAB member Dr. Janice Robertson
attended the 31st Virtual International Symposium on ALS/MND that was held virtually on December 9-11th, 2020.

Dr. Robertson’s Ph.D. student Marc Shenouda presented ‘Identification and validation of small molecules targeting the amyloidogenic core of TDP-43 as therapeutics for ALS/FTLD’ on identifying small molecules and evaluating them in cell-free and cell-based assays. The results indicate significant activity in both kinds of assays, suggesting significant potential for Treventis compounds as anti-misfolding agents against TDP isoforms. Further work will establish a complete Target Product Profile and a target engagement model for advancement of compounds in lead optimization, ultimately aiming to provide a drug(s) for testing in the clinic.

#pf-body .pf-caption img.blockImage { margin: 0!important; float: none; } #pf-body a.elementor-icon, #pf-body a.skip-link{display:none!important;} /*#pf-content {max-width:100%!important}*/ #pf-content img.mediumImage, #pf-content figure.mediumImage { margin-left: auto!important; margin-right: auto!important; clear: both!important; float: none!important; display: block!important; }